Zhejiang Huahai Pharmaceutical Co Ltd Asset Resilience Ratio
Zhejiang Huahai Pharmaceutical Co Ltd asset resilience ratio. Zhejiang Huahai Pharmaceutical Co Ltd (600521) has an Asset Resilience Ratio of 0.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Zhejiang Huahai Pharmaceutical Co Ltd (600521) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Huahai Pharmaceutical Co Ltd (2003–2025)
Asset resilience ratio of Zhejiang Huahai Pharmaceutical Co Ltd from 2003 to 2025. This chart shows how Zhejiang Huahai Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 600521 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Huahai Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zhejiang Huahai Pharmaceutical Co Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥75.23 Million | 0.34% |
| Total Liquid Assets | CN¥75.23 Million | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Huahai Pharmaceutical Co Ltd maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Huahai Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Huahai Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Zhejiang Huahai Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2003–2025)
Zhejiang Huahai Pharmaceutical Co Ltd asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Zhejiang Huahai Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.35% | CN¥75.98 Million ≈ $11.12 Million |
CN¥21.50 Billion ≈ $3.15 Billion |
+0.05pp |
| 2024-12-31 | 0.30% | CN¥60.79 Million ≈ $8.90 Million |
CN¥20.26 Billion ≈ $2.96 Billion |
-0.20pp |
| 2023-12-31 | 0.50% | CN¥93.04 Million ≈ $13.61 Million |
CN¥18.60 Billion ≈ $2.72 Billion |
-0.29pp |
| 2022-12-31 | 0.79% | CN¥143.07 Million ≈ $20.94 Million |
CN¥18.15 Billion ≈ $2.66 Billion |
+0.78pp |
| 2021-12-31 | 0.01% | CN¥1.01 Million ≈ $148.09K |
CN¥15.47 Billion ≈ $2.26 Billion |
+0.01pp |
| 2018-12-31 | 0.00% | CN¥2.05K ≈ $299.56 |
CN¥10.37 Billion ≈ $1.52 Billion |
-3.92pp |
| 2014-12-31 | 3.92% | CN¥177.00 Million ≈ $25.90 Million |
CN¥4.51 Billion ≈ $659.96 Million |
+3.58pp |
| 2013-12-31 | 0.35% | CN¥15.60 Million ≈ $2.28 Million |
CN¥4.47 Billion ≈ $653.53 Million |
+0.18pp |
| 2012-12-31 | 0.17% | CN¥5.43 Million ≈ $794.07K |
CN¥3.22 Billion ≈ $470.69 Million |
-0.05pp |
| 2011-12-31 | 0.21% | CN¥5.53 Million ≈ $809.36K |
CN¥2.58 Billion ≈ $377.10 Million |
-10.70pp |
| 2004-12-31 | 10.91% | CN¥97.71 Million ≈ $14.30 Million |
CN¥895.55 Million ≈ $131.05 Million |
+9.36pp |
| 2003-12-31 | 1.55% | CN¥12.01 Million ≈ $1.76 Million |
CN¥774.68 Million ≈ $113.36 Million |
-- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging componen… Read more